WO2002090552A3 - Use of 2'-5'-oligoadenylate synthetase and/or rnasel or nucleic acids encoding them for diagnosis, prophylaxis or treatment of wound healing - Google Patents

Use of 2'-5'-oligoadenylate synthetase and/or rnasel or nucleic acids encoding them for diagnosis, prophylaxis or treatment of wound healing Download PDF

Info

Publication number
WO2002090552A3
WO2002090552A3 PCT/EP2002/005113 EP0205113W WO02090552A3 WO 2002090552 A3 WO2002090552 A3 WO 2002090552A3 EP 0205113 W EP0205113 W EP 0205113W WO 02090552 A3 WO02090552 A3 WO 02090552A3
Authority
WO
WIPO (PCT)
Prior art keywords
rnasel
diagnosis
treatment
nucleic acids
acids encoding
Prior art date
Application number
PCT/EP2002/005113
Other languages
French (fr)
Other versions
WO2002090552A2 (en
Inventor
Joern-Peter Halle
Andreas Goppelt
Johannes Regenbogen
Birgit Reitmaier
Original Assignee
Switch Biotech Ag
Joern-Peter Halle
Andreas Goppelt
Johannes Regenbogen
Birgit Reitmaier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2001122206 external-priority patent/DE10122206A1/en
Application filed by Switch Biotech Ag, Joern-Peter Halle, Andreas Goppelt, Johannes Regenbogen, Birgit Reitmaier filed Critical Switch Biotech Ag
Priority to AU2002341207A priority Critical patent/AU2002341207A1/en
Publication of WO2002090552A2 publication Critical patent/WO2002090552A2/en
Publication of WO2002090552A3 publication Critical patent/WO2002090552A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/53—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Abstract

Use of polypeptides, or nucleic acids encoding them, of a 2'-5'-oligoadenylate synthetase and/or RNAseL for the diagnosis and/or prevention and/or treatment in association with wound healing and/or its pathological disorders, particularly venous ulcers and diabetes-associated poorly healing wounds, and their use for identifying pharmacologically active substances.
PCT/EP2002/005113 2001-05-08 2002-05-08 Use of 2'-5'-oligoadenylate synthetase and/or rnasel or nucleic acids encoding them for diagnosis, prophylaxis or treatment of wound healing WO2002090552A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002341207A AU2002341207A1 (en) 2001-05-08 2002-05-08 Use of 2'-5'-oligoadenylate synthetase and/or rnasel or nucleic acids encoding them for diagnosis, prophylaxis or treatment of wound healing

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE2001122206 DE10122206A1 (en) 2001-05-08 2001-05-08 Novel use of 2',5'-oligoadenylate synthetase or RNAseL polypeptides, nucleic acids encoding polypeptides, cell expressing peptides and nucleic acids or antibody for analyzing, diagnosing, or treating wound healing
DE10122206.8 2001-05-08
US32294901P 2001-09-17 2001-09-17
US60/322,949 2001-09-17

Publications (2)

Publication Number Publication Date
WO2002090552A2 WO2002090552A2 (en) 2002-11-14
WO2002090552A3 true WO2002090552A3 (en) 2004-08-05

Family

ID=26009247

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/005113 WO2002090552A2 (en) 2001-05-08 2002-05-08 Use of 2'-5'-oligoadenylate synthetase and/or rnasel or nucleic acids encoding them for diagnosis, prophylaxis or treatment of wound healing

Country Status (2)

Country Link
AU (1) AU2002341207A1 (en)
WO (1) WO2002090552A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0208928D0 (en) * 2002-04-19 2002-05-29 Imp College Innovations Ltd Methods
CA2543789A1 (en) 2003-10-23 2005-05-06 Illumigen Biosciences, Inc. Detection of mutations in a gene associated with resistance to viral infection, oas1
NZ591879A (en) * 2003-10-23 2012-11-30 Kineta Two Llc Detection of mutations in a gene associated with resistance to viral infection, OAS1
TWI415944B (en) * 2004-02-06 2013-11-21 Kineta Two Llc Detection of mutations in a gene associated with resistance to viral infection, oasi
UA95446C2 (en) 2005-05-04 2011-08-10 Іллюміджен Байосайєнсіз, Інк. Mutations in oas1 genes
EP2123748A1 (en) * 2008-05-20 2009-11-25 Institut Pasteur 2'-5'-oligoadenylate synthetase 3 for preventing and treating positive-sense single-stranded rna virus infection
US20110104138A1 (en) * 2009-11-03 2011-05-05 Institut Pasteur Use of the innate immunity gene oasl for preventing or treating infection with negative strand rna viruses
CN115595315A (en) * 2021-06-28 2023-01-13 四川大学华西医院（Cn） Novel application of ribonuclease I in pain inhibition medicine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0797998A1 (en) * 1995-11-17 1997-10-01 Toray Industries, Inc. Endothelial cell protective

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0797998A1 (en) * 1995-11-17 1997-10-01 Toray Industries, Inc. Endothelial cell protective

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JUSTESEN-J ET AL.: "Gene structure and function of the 2'-5'-oligoadenylate synthetase family", CELLULAR AND MOLECULAR LIFE SCIENCES, vol. 57, no. 11, October 2000 (2000-10-01), pages 1593 - 1612, XP001157584 *
KHANNA K K ET AL: "ABSENCE OF THE 40-KDA FORM OF 2'-5' OLIGOADENYLATE SYNTHETASE AND ITS CORRESPONDING MESSENGER RNA FROM SKIN FIBROBLASTS DERIVED FROM ALZHEIMER DISEASE PATIENTS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 88, no. 13, 1991, 1991, pages 5852 - 5856, XP002243034, ISSN: 0027-8424 *
SCHMID-P ET AL.: "The type I interferon system is locally activated in psoriatic lesions", JOURNAL OF INTERFERON RESEARCH, vol. 14, 1994, pages 229 - 234, XP008017805 *

Also Published As

Publication number Publication date
AU2002341207A1 (en) 2002-11-18
WO2002090552A2 (en) 2002-11-14

Similar Documents

Publication Publication Date Title
AU2002233643A1 (en) Methods of treating diseases in association with decrease in the expression of AOP-1 gene or AOP-1 and remedies for the diseases
DE69832446D1 (en) Device for detecting the contact between the electrode and body tissue.
EP1360965A4 (en) Methods of treating diseases in association with decrease in the expression of aop-1 gene or aop-1 and remedies for the diseases
AU775126C (en) Substituted oxazolidinones and their use in the field of blood coagulation
DE69535349D1 (en) An implantable active medical device having means for discriminating between resting and active states of the patient
WO2002098444A3 (en) Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
EP1455778A4 (en) Methods for the treatment of peripheral neural and vascular ailments
EP1576963A3 (en) Use of botulinum toxin in the treatment of pain due to an infection
AU2001293553A1 (en) Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment
EP1769791A3 (en) Treatment of Alzheimer's disease with cell cycle inhibitors
AU2002308348A1 (en) Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours
IL143699A0 (en) Use of polypeptides or nucleic acids for the diagnosis or treatment of skin disorders and wound healing and for the identification of pharmacologically active substances
WO2003030927A3 (en) Use of thymulin-like peptides for making pain-relieving medicines
WO2001056627A8 (en) Medical device coated with antimicrobial peptides
AU2001270484A1 (en) Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations
AU2003229284A1 (en) Active substances for the treatment, diagnosis and prophylaxis of diseases in which abnormal protein structures occur
HK1068106A1 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
WO2002090552A3 (en) Use of 2'-5'-oligoadenylate synthetase and/or rnasel or nucleic acids encoding them for diagnosis, prophylaxis or treatment of wound healing
PT1206257E (en) USE OF AMINO ACIDS FOR THE MANUFACTURE OF MEDICINES INTENDED FOR THE TREATMENT OF INSULIN RESISTANCE
AU3593599A (en) Drugs for reducing vaginal acidity and treatment of vaginitis, and the use thereof
WO2001089558A3 (en) Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
WO2000059940A3 (en) Platelet-derived growth factor related gene and protein
AU2001253886A1 (en) Methylxanthines in the diagnosis and treatment of autistic disorder
AU4259299A (en) New sequences of tt viruses for use in diagnosis, prevention and treatment of ttv infections
WO1999014322A3 (en) Allelic variant of human stat3

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP